SeekingAlpha · Aug 8, 2026
EyePoint: Phase 3 Design Creates A More Valuable Durability Story
EyePoint nears a binary catalyst: Phase III LUGANO DURAVYU wet AMD data in Aug. 2026. Click here to read more about the EYPT stock.
EY
NASDAQ · EYPT
EyePoint Pharmaceuticals, Inc.
Healthcare · Biotechnology
$14.75
Up+$1.27 (+9.42%)
Updated Aug 16, 2026, 8:55 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.11B
- P/E ratio
- -5.5
- Dividend yield
- 0.00%
- 52-week range
- $9.65 – $19.11
- Volume
- 2.51M
- Avg. volume
- 1.29M
Price performance
EYPT price history
1M range · 20 trading sessions · Daily adjusted prices
EYPT closed at $14.75 after 20 trading sessions, up 16.51% for the selected period.
- Last close
- $14.75
- Period change
- +16.51%
- Period low
- $11.67
- Period high
- $14.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $13.53 | $14.76 | $13.40 | $14.75 | 2.51M |
| Aug 13, 2026 | $13.59 | $13.6938 | $13.25 | $13.48 | 1.2M |
| Aug 12, 2026 | $13.05 | $13.77 | $13.02 | $13.53 | 2.26M |
| Aug 11, 2026 | $13.105 | $13.105 | $12.37 | $13.05 | 2.06M |
| Aug 10, 2026 | $14.22 | $14.32 | $13.02 | $13.07 | 1.76M |
| Aug 7, 2026 | $13.04 | $14.08 | $13.0286 | $13.89 | 1.66M |
| Aug 6, 2026 | $12.25 | $13.03 | $12.005 | $12.83 | 2.24M |
| Aug 5, 2026 | $11.88 | $12.74 | $11.849 | $12.25 | 2.45M |
| Aug 4, 2026 | $12.44 | $12.70 | $11.54 | $11.67 | 2.93M |
| Aug 3, 2026 | $12.34 | $12.51 | $12.02 | $12.42 | 1.48M |
| Jul 31, 2026 | $12.81 | $12.83 | $12.04 | $12.25 | 1.71M |
| Jul 30, 2026 | $12.17 | $13.00 | $11.79 | $12.86 | 1.56M |
| Jul 29, 2026 | $11.98 | $12.355 | $11.555 | $11.92 | 2.05M |
| Jul 28, 2026 | $12.34 | $12.53 | $11.72 | $11.96 | 1.7M |
| Jul 27, 2026 | $12.48 | $13.025 | $12.17 | $12.41 | 1.39M |
| Jul 24, 2026 | $12.45 | $12.4975 | $12.06 | $12.19 | 1.47M |
| Jul 23, 2026 | $12.45 | $12.89 | $12.295 | $12.47 | 1.28M |
| Jul 22, 2026 | $12.81 | $13.04 | $12.52 | $12.66 | 1.06M |
| Jul 21, 2026 | $12.66 | $13.23 | $12.45 | $13.05 | 1.59M |
| Jul 20, 2026 | $13.27 | $13.79 | $12.65 | $12.66 | 1.1M |
Latest EYPT news
The latest Smart Investors Daily articles mentioning EYPT.
Stock researchCompany · Overview
EYPT research
Overview
Company profile and research snapshot.
Company profile
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $33.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Chardan Capital | Buy | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | Stifel | Buy | — |
| Jul 1, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55
Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and raises the price target from $47 to $55.
Benzinga · Aug 6, 2026
HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $27.
ChartMill · Aug 5, 2026
EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears
EyePoint beats Q2 revenue but posts wider loss; stock rises as DURAVYU Phase 3 wet AMD data nears in August 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
